| BAC |
Report |
NII (Q2 2026) |
BEAT |
pred ~$16.20B vs. cons $16.03B |
MEDIUM |
| BAC |
Report |
Sales & Trading ex-DVA (Q2 2026) |
BEAT |
pred ~$6.45B vs. cons $6.28B |
MEDIUM |
| BAC |
Report |
Operating EPS (Q2 2026) |
BEAT |
pred ~$1.18 vs. cons $1.128 |
MEDIUM |
| BAC |
Guide |
FY 2026 NII Growth (FY 2026) |
BETTER |
guide ~'up 7-9%' vs. cons $64.78B (up ~6.7%) |
MEDIUM |
| BAC |
Guide |
FY 2026 Operating Leverage (FY 2026) |
BETTER |
guide ~'>250bps' vs. cons 59.96% efficiency ratio |
MEDIUM |
| BAC |
Guide |
Consumer Credit Tone (qualitative) |
UNCHANGED |
Stable/benign; card NCO rate ~48-50bps |
MEDIUM |
| BAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.2% |
— |
LOW |
| BAC |
Return |
5-day cumulative residual |
-2.0% (FADE) |
FADE — Archetype A / large pre-print run; modest FY NII raise digested; Q3 sell-side revisions small (~$150-200M); stock gives back portion of +6.3% pre-print outperformance over 5 days |
LOW |